C&EN White Paper
Accelerating Development of Poorly Soluble Drug Candidates Through Quality-by-Design
Brought to you by Aenova
Overview

Over 80% of candidate drugs have poor solubility, leading to low bioavailability. This challenge slows down pharmaceutical R&D pipelines, delaying availability of drugs to patients in need.

In this white paper, we introduce a Quality-by-Design (QbD) formulation approach to addresses solubility challenges. We discuss the use of key technologies such as lipid-based formulations and amorphous solid dispersions and how integrating QbD from early development can accelerate a drug candidates' journey to market.

Key Objectives:
  • Highlight the prevalence and impact of poor solubility on drug development pipelines
  • Introduce a QbD approach as a solution to improve solubility and accelerate timelines
  • Demonstrate through a case study how optimizing formulation can improve bioavailability

Brought to you by:
Aenova logo
Please complete the form to download the white paper.
*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society and its sponsor via email. You understand that you can withdraw your consent at any time. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.

Copyright © 2025 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy